Keeping Track: Kite’s Tecartus Is Third CAR-T With US FDA Approval; Submissions Round-Up
Executive Summary
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
Jazz Gets Second Indication For Xywav As First Therapy For Idiopathic Hypersomnia
Following last year’s approval in cataplexy for the Xyrem follow-on, Jazz could realize additional revenue of up to $500m annually with the first and only approval in IH, analysts say.
BMS’ Breyanzi Beats COVID-19 Constraints, Emerges As First RMAT Approval
After missing user fee date due to inspection delay, US FDA clears the CAR-T therapy for treatment of adults with relapsed or refractory large B-cell lymphoma.
EU Gene Therapy Submissions, Approvals Expected To Pick Up In 2021
Coming year could feature first-time approvals in the EU for at least five gene therapies.